Oxular’s Senior Medical Advisor, Prof. Marc de Smet, presented on “Managing CME via the Suprachoroidal Space” at the December 2021 IOIS Conference. His talk included an update on a hard-to-treat postsurgical macular edema patient. The Oxulumis® posterior suprachoroidal microcatheter was used under compassionate use for the administration of Triesence®, an approved triamcinolone acetonide suspension. The data below shows both a gain in visual acuity and a reduction in CMT, with a duration now approaching one year, following only two Triesence® Oxulumis® microcatheterizations.
We’re thrilled that Marc’s patient has seen such sustained benefits from drug delivery into the posterior suprachoroidal space – especially as this was a very complex, refractory case with the patient suffering significantly impaired vision. You can watch or read Marc’s full presentation below.
